AYTU BIOPHARMA, INC Revenue from Contract with Customer, Including Assessed Tax
AYTU BIOPHARMA, INC (AYTU) reported Revenue from Contract with Customer, Including Assessed Tax of $13.48 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2021-05-17
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for the quarter ending 2021-03-31 was $13.48M, a 65.30% increase year-over-year.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for the quarter ending 2020-12-31 was $15.15M, a 377.04% increase year-over-year.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for the quarter ending 2020-09-30 was $13.52M, a 838.89% increase year-over-year.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for the quarter ending 2020-06-30 was $14.86M, a 763.50% increase year-over-year.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for fiscal 2020 was $27.63M, a 277.49% increase from fiscal 2019.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for fiscal 2019 was $7.32M, a 100.00% increase from fiscal 2018.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for fiscal 2018 was $3.66M, a 13.61% increase from fiscal 2017.
- AYTU BIOPHARMA, INC revenue from contract with customer, including assessed tax for fiscal 2017 was $3.22M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-03-31 | $13.48M 10-Q · filed 2021-05-17 | $28.63M derived: sum of 2 quarters · filed 2021-05-17 | $42.15M 10-Q · filed 2021-05-17 | $57.01M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2020-12-31 | $15.15M 10-Q · filed 2021-02-11 | $28.67M 10-Q · filed 2021-02-11 | $43.53M derived: sum of 3 quarters · filed 2021-02-11 | $51.68M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2020-09-30 | $13.52M 10-Q · filed 2020-11-12 | $28.38M derived: sum of 2 quarters · filed 2020-11-12 | $36.54M derived: sum of 3 quarters · filed 2021-05-17 | $39.71M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2020-06-30 | $14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $23.02M derived: sum of 2 quarters · filed 2021-05-17 | $26.19M derived: sum of 3 quarters · filed 2021-05-17 | $27.63M 10-K · filed 2020-10-06 | ||||
| 2020-03-31 | $8.16M 10-Q · filed 2021-05-17 | $8.16M 10-Q · filed 2020-05-15 | $11.33M derived: sum of 2 quarters · filed 2021-05-17 | $12.77M 10-Q · filed 2021-05-17 | $12.77M 10-Q · filed 2020-05-15 | $14.49M derived: sum of 4 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $3.18M 10-Q · filed 2021-02-11 | $3.17M 10-Q · filed 2020-02-14 | $4.62M 10-Q · filed 2021-02-11 | $4.62M 10-Q · filed 2020-02-14 | $6.34M derived: sum of 3 quarters · filed 2021-02-11 | $8.71M derived: sum of 4 quarters · filed 2021-02-11 | ||
| 2019-09-30 | $1.44M 10-Q · filed 2020-11-12 | $3.16M derived: sum of 2 quarters · filed 2020-11-12 | $5.53M derived: sum of 3 quarters · filed 2020-11-12 | $7.33M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $4.09M derived: sum of 2 quarters · filed 2020-10-06 | $5.89M derived: sum of 3 quarters · filed 2020-10-06 | $7.32M 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | $2.37M 10-Q · filed 2020-05-15 | $4.17M derived: sum of 2 quarters · filed 2020-05-15 | $5.60M 10-Q · filed 2020-05-15 | $6.52M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $1.79M 10-Q · filed 2020-02-14 | $1.80M 10-Q · filed 2019-02-07 | $3.23M 10-Q · filed 2020-02-14 | $3.23M 10-Q · filed 2019-02-07 | $4.15M derived: sum of 3 quarters · filed 2020-02-14 | $4.76M derived: sum of 4 quarters · filed 2020-02-14 | ||
| 2018-09-30 | $1.43M 10-Q · filed 2019-11-14 | $1.43M 10-Q · filed 2018-11-07 | $2.36M derived: sum of 2 quarters · filed 2019-11-14 | $2.96M derived: sum of 3 quarters · filed 2019-11-14 | $4.02M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $925.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $1.53M derived: sum of 2 quarters · filed 2019-09-26 | $2.58M derived: sum of 3 quarters · filed 2019-09-26 | $3.66M 10-K · filed 2019-09-26 | $3.66M 10-K · filed 2018-09-06 | |||
| 2018-03-31 | $607.00K 10-Q · filed 2019-05-14 | $1.66M derived: sum of 2 quarters · filed 2019-05-14 | $2.73M 10-Q · filed 2019-05-14 | |||||
| 2017-12-31 | $1.05M 10-Q · filed 2019-05-14 | $2.13M 10-Q · filed 2019-05-14 | ||||||
| 2017-09-30 | $1.08M 10-Q · filed 2018-11-07 | |||||||
| 2017-06-30 | $3.22M 10-K · filed 2018-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |